These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 32630835)

  • 1. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.
    Naeem M; Majeed S; Hoque MZ; Ahmad I
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Increase On-Target and Reduce Off-Target Effects of the CRISPR/Cas9 System in Plants.
    Hajiahmadi Z; Movahedi A; Wei H; Li D; Orooji Y; Ruan H; Zhuge Q
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31366028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes.
    Jacobi AM; Rettig GR; Turk R; Collingwood MA; Zeiner SA; Quadros RM; Harms DW; Bonthuis PJ; Gregg C; Ohtsuka M; Gurumurthy CB; Behlke MA
    Methods; 2017 May; 121-122():16-28. PubMed ID: 28351759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome editing via delivery of Cas9 ribonucleoprotein.
    DeWitt MA; Corn JE; Carroll D
    Methods; 2017 May; 121-122():9-15. PubMed ID: 28410976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of Cas9 and single-guided RNAs in
    Qiao J; Li W; Lin S; Sun W; Ma L; Liu Y
    Commun Biol; 2019; 2():161. PubMed ID: 31069270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly efficient DNA-free gene disruption in the agricultural pest Ceratitis capitata by CRISPR-Cas9 ribonucleoprotein complexes.
    Meccariello A; Monti SM; Romanelli A; Colonna R; Primo P; Inghilterra MG; Del Corsano G; Ramaglia A; Iazzetti G; Chiarore A; Patti F; Heinze SD; Salvemini M; Lindsay H; Chiavacci E; Burger A; Robinson MD; Mosimann C; Bopp D; Saccone G
    Sci Rep; 2017 Aug; 7(1):10061. PubMed ID: 28855635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the CRISPR/Cas system for genome editing in microalgae.
    Zhang YT; Jiang JY; Shi TQ; Sun XM; Zhao QY; Huang H; Ren LJ
    Appl Microbiol Biotechnol; 2019 Apr; 103(8):3239-3248. PubMed ID: 30877356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs.
    Fu Y; Reyon D; Joung JK
    Methods Enzymol; 2014; 546():21-45. PubMed ID: 25398334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application.
    Sun B; Chen H; Gao X
    J Control Release; 2021 Sep; 337():698-717. PubMed ID: 34364918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing.
    Li J; Hong S; Chen W; Zuo E; Yang H
    J Genet Genomics; 2019 Nov; 46(11):513-521. PubMed ID: 31911131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant.
    Tran MTN; Khalid MKNM; Pébay A; Cook AL; Liang HH; Wong RCB; Craig JE; Liu GS; Hung SS; Hewitt AW
    Mol Vis; 2019; 25():174-182. PubMed ID: 30996586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.